Rigel Pharmaceuticals, Inc.
RIGLNASDAQHealthcare● Active
$30.14
+$0.21(+0.68%)
Market Cap$557560181
P/E Ratio—
52W High$52.24
52W Low$18.14
Rigel Pharmaceuticals, Inc. (RIGL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RIGL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.44
Est. $0.74 · -40.5%
Revenue
$0.06B
Est. $0.06B · -5.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RIGL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.21 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | May 5, 2026 | $0.74 | $0.44 | -40.5% | $0.06B | $0.06B | -5.7% |
| ▼ Q1 FY2026 | Mar 3, 2026 | $1.33 | $1.14 | -14.3% | $0.07B | $0.07B | +1.6% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.93 | $1.46 | +57.0% | $0.07B | $0.07B | +1.5% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $1.97 | $3.28 | +66.5% | $0.10B | $0.06B | +63.2% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.14 | $0.63 | +350.0% | $0.05B | $0.05B | +10.4% |
| ▲ Q1 FY2025 | Mar 4, 2025 | $0.30 | $0.80 | +166.7% | $0.06B | $0.06B | +0.0% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.06 | $0.70 | +1066.7% | $0.06B | $0.05B | +16.6% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
$0.44
EPS Est.
$0.74
EPS Surpr.
-40.5%
Revenue
$0.06B
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
$1.14
EPS Est.
$1.33
EPS Surpr.
-14.3%
Revenue
$0.07B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$1.46
EPS Est.
$0.93
EPS Surpr.
+57.0%
Revenue
$0.07B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$3.28
EPS Est.
$1.97
EPS Surpr.
+66.5%
Revenue
$0.10B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.63
EPS Est.
$0.14
EPS Surpr.
+350.0%
Revenue
$0.05B
Q1 FY2025
Mar 4, 2025Beat
EPS Actual
$0.80
EPS Est.
$0.30
EPS Surpr.
+166.7%
Revenue
$0.06B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.70
EPS Est.
$0.06
EPS Surpr.
+1066.7%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.70 | $1.13 | $1.29 | 1 |
| Q3 FY2027 | $0.59 | $0.94 | $1.08 | 1 |
| Q2 FY2027 | $0.54 | $0.87 | $1.00 | 1 |
| Q1 FY2027 | $0.37 | $0.60 | $0.69 | 1 |
| Q4 FY2026 | $0.76 | $1.21 | $1.39 | 1 |
| Q3 FY2026 | $1.07 | $1.22 | $1.37 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.0B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -40.5% | $29.54 | $28.09 | -4.91% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -14.3% | $34.62 | $33.02 | -4.62% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +57.0% | $30.65 | $28.38 | -7.41% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +66.5% | $22.67 | $24.24 | +6.93% |
| ▲ Q2 FY2025 | May 6, 2025 | +350.0% | $19.11 | $18.26 | -4.45% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +166.7% | $22.37 | $22.08 | -1.30% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +1066.7% | $15.08 | $15.44 | +2.39% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +83.8% | $8.80 | $9.33 | +6.02% |
Q2 FY2026-4.91%
Report Date
May 5, 2026
EPS Beat/Miss
-40.5%
Price Before
$29.54
Price After
$28.09
Q1 FY2026-4.62%
Report Date
Mar 3, 2026
EPS Beat/Miss
-14.3%
Price Before
$34.62
Price After
$33.02
Q4 FY2025-7.41%
Report Date
Nov 4, 2025
EPS Beat/Miss
+57.0%
Price Before
$30.65
Price After
$28.38
Q3 FY2025+6.93%
Report Date
Aug 5, 2025
EPS Beat/Miss
+66.5%
Price Before
$22.67
Price After
$24.24
Q2 FY2025-4.45%
Report Date
May 6, 2025
EPS Beat/Miss
+350.0%
Price Before
$19.11
Price After
$18.26
Q1 FY2025-1.30%
Report Date
Mar 4, 2025
EPS Beat/Miss
+166.7%
Price Before
$22.37
Price After
$22.08
Q4 FY2024+2.39%
Report Date
Nov 7, 2024
EPS Beat/Miss
+1066.7%
Price Before
$15.08
Price After
$15.44
Q3 FY2024+6.02%
Report Date
Aug 6, 2024
EPS Beat/Miss
+83.8%
Price Before
$8.80
Price After
$9.33
Avg Beat Reaction+0.36%
Avg Miss Reaction-4.77%
Beat Rate6 / 8 quarters
Largest Move-7.41% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RIGL ends December
Rigel Pharmaceuticals, Inc. (RIGL) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.44 — missing the analyst consensus of $0.74 by -40.5%. The next RIGL earnings date is expected around September 1, 2026.
Each quarter, investors track RIGL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RIGL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RIGL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RIGL earnings · 5 questionsRigel Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. RIGL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RIGL historically reports after market close (AMC).
RIGL earnings datewhen is RIGL earningsRIGL next earnings datewhen does RIGL report earningsRIGL earnings calendar
▸ Source: FMP · Rigel Pharmaceuticals, Inc. SEC filings · US GAAP · Rigel Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026